Redenti, S; Marcovich, I; De Vita, T; Perez, C; De Zorzi, R; Demitri, N; Perez, DI; Bottegoni, G; Bisignano, P; Bissaro, M; Moro, S; Martinez, A; Storici, P; Spalluto, G; Cavalli, A; Federico, S in [Redenti, Sara; Marcovich, Irene; De Zorzi, Rita; Spalluto, Giampiero; Federico, Stephanie] Univ Trieste, Dept Chem & Pharmaceut Sci, Via Licio Giorgeri 1, I-34127 Trieste, Italy; [De Vita, Teresa; Cavalli, Andrea] Ist Italiano Tecnol, Drug Discovery & Dev D3, Via Morego 30, I-16163 Genoa, Italy; [Perez, Concepcion; Perez, Daniel I.; Martinez, Ana] CSIC, Ctr Invest Biol, Ave Ramiro Maeztu 9, Madrid 28040, Spain; [Demitri, Nicola; Storici, Paola] Elettra Sincrotrone Trieste SCpA, SS 14,Km 163-5,AREA Sci Pk, I-34149 Trieste, Italy; [Bottegoni, Giovanni] Univ Birmingham, Sir Robert Aitken Inst Med Res, Coll Med & Dent Sci, Sch Pharm,Inst Clin Sci, Edgbaston B15 2TT, England; [Bisignano, Paola] Univ Calif San Francisco, Cardiovasc Res Inst, 555 Mission Bay Blvd South, San Francisco, CA 94158 USA; [Bissaro, Maicol; Moro, Stefano] Univ Padua, Dept Pharmaceut & Pharmacol Sci, Mol Modeling Sect, Via Marzolo 5, I-35131 Padua, Italy published A Triazolotriazine-Based Dual GSK-3 beta/CK-1 delta Ligand as a Potential Neuroprotective Agent Presenting Two Different Mechanisms of Enzymatic Inhibition in 2019.0, Cited 33.0. HPLC of Formula: C2H4N4. The Name is 1H-1,2,4-Triazol-5-amine. Through research, I have a further understanding and discovery of 61-82-5.
Glycogen synthase kinase 3 beta (GSK-3 beta) and casein kinase 1 delta (CK-1 delta) are emerging targets for the treatment of neuroinflammatory disorders, including Parkinson’s disease. An inhibitor able to target these two kinases was developed by docking-based design. Compound 12, 3-(7-amino-5-(cyclohexylamino)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-2-yl)-2-cyanoacrylamide, showed combined inhibitory activity against GSK-3 beta and CK-1 delta [IC50(GSK-3 beta)=0.17 mu m; IC50(CK-1 delta)=0.68 mu m]. In particular, classical ATP competition was observed against CK-1 delta, and a co-crystal of compound 12 inside GSK-3 beta confirmed a covalent interaction between the cyanoacrylamide warhead and Cys199, which could help in the development of more potent covalent inhibitors of GSK-3 beta. Preliminary studies on in vitro models of Parkinson’s disease revealed that compound 12 is not cytotoxic and shows neuroprotective activity. These results encourage further investigations to validate GSK-3 beta/CK-1 delta inhibition as a possible new strategy to treat neuroinflammatory/degenerative diseases.
Bye, fridends, I hope you can learn more about C2H4N4, If you have any questions, you can browse other blog as well. See you lster.. HPLC of Formula: C2H4N4
Reference:
Article; Safari, Niloufar; Shirini, Farhad; Tajik, Hassan; Journal of Molecular Structure; vol. 1201; (2020);,
1,2,3-Triazole – Wikipedia,
Triazoles – an overview | ScienceDirect Topics